FY2024 Earnings Forecast for ALDX Issued By Leerink Partnrs

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Investment analysts at Leerink Partnrs lowered their FY2024 EPS estimates for shares of Aldeyra Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will post earnings of ($0.95) per share for the year, down from their prior forecast of $0.70. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.89) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ Q4 2024 earnings at ($0.28) EPS, FY2025 earnings at $2.00 EPS and FY2026 earnings at ($0.05) EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, hitting analysts’ consensus estimates of ($0.25).

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Friday, August 9th.

Aldeyra Therapeutics Price Performance

Shares of ALDX opened at $4.21 on Monday. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. Aldeyra Therapeutics has a 1 year low of $2.43 and a 1 year high of $6.55. The company has a 50 day simple moving average of $5.45 and a two-hundred day simple moving average of $4.60.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of hedge funds have recently bought and sold shares of the business. US Bancorp DE purchased a new stake in shares of Aldeyra Therapeutics during the 3rd quarter valued at about $30,000. SG Americas Securities LLC purchased a new position in Aldeyra Therapeutics during the second quarter worth $38,000. Paloma Partners Management Co bought a new position in Aldeyra Therapeutics during the third quarter valued at $62,000. Diversified Trust Co purchased a new stake in shares of Aldeyra Therapeutics in the second quarter valued at $41,000. Finally, King Wealth Management Group lifted its holdings in shares of Aldeyra Therapeutics by 24.5% in the 3rd quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 2,700 shares during the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.